Drug Type Small molecule drug |
Synonyms |
Target |
Action inhibitors |
Mechanism Cbl-b inhibitors(E3 ubiquitin-protein ligase CBL-B inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (United States), Orphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Arm Injuries | Phase 3 | United States | 10 Feb 2025 | |
Peripheral Nerve Injuries | Phase 3 | United States | 10 Feb 2025 | |
Facial Paralysis | Phase 2 | United States | 12 Jul 2022 |
Phase 2 | - | (jhadnlhkfg) = clinically and statistically meaningful changes observed at eight and 24-week intervals. kfyljtsswp (fszfzxadpi ) View more | Positive | 22 Feb 2024 | |||
Standard of Care | |||||||
Phase 2 | 60 | (spyofxjzbw) = the MHQ change at baseline in Total Score at 12 weeks demonstrated that NTX-001 treatment was numerically improved over SOC but did not reach statistical significance for this global function assessment. lhzmhekmuo (pxplidqkyk ) View more | Positive | 08 Jan 2024 | |||
SOC |